Follow our progress.

Milestones in our journey to reinvent genetic testing.

Press Releases

Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing

Invitae research highlights utility of proactive genetic screening, importance of assessing secondary findings in genetic testing

April 10, 2018

Data presented at annual American College of Medical Genetics meeting

Researchers from Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, will present findings showing proactive genetic health screening reveals medically significant findings for a substantial portion of patients, and looking for secondary findings during genetic testing provides a substantial yield of actionable risk factors for disease. The studies are among the company’s data being presented this week at the American College of Medical Genetics (ACMG) annual ...

Read more


Invitae Announces Pricing of Public Offering of Common Stock

Invitae Announces Pricing of Public Offering of Common Stock

March 28, 2018

Invitae Corporation (NYSE: NVTA) today announced the pricing on March 27, 2018 of an underwritten public offering of 11,111,111 shares of its common stock at a price to the public of $4.50 per share. All of the shares are being sold by Invitae. The gross proceeds to Invitae from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on ...

Read more


Invitae Announces Proposed Public Offering of Common Stock

Invitae Announces Proposed Public Offering of Common Stock

March 26, 2018

Invitae Corporation (NYSE: NVTA) today announced that it has commenced an underwritten public offering of $50.0 million of shares of its common stock, before deducting underwriting discounts and commissions and other offering expenses. All of the shares are being offered by Invitae. In addition, Invitae expects to grant the underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The ...

Read more


Invitae expands network of patients in rare and ultra-rare diseases

Invitae expands network of patients in rare and ultra-rare diseases

March 23, 2018

No Stomach For Cancer among five advocacy groups establishing registry networks to connect patients, clinicians and researchers

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced an expansion of its network of rare and ultra-rare patient registries in its Patient Insights NetworkTM (PIN) program to include five additional collaborations with leading advocacy groups across a variety of genetic conditions. The programs are designed to empower patients to be active participants in their networks and ...

Read more


Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information

Invitae partners with KEW, Inc. to develop somatic mutation detection capabilities to improve cancer care by providing comprehensive genomic information

March 16, 2018

Combining germline and somatic information provides more comprehensive view from diagnosis through treatment

Detailed genomic characterization of tumors rapidly enhancing drug development through biomarker-driven clinical trials

Invitae Corporation (NYSE: NVTA) and KEW, Inc. today announced a collaboration to develop comprehensive genomic profiling solutions for sequencing tumor DNA on Invitae’s next generation sequencing (NGS) platform. By adding KEW’s somatic mutation detection capabilities to Invitae’s extensive portfolio of diagnostic genetic testing panels for hereditary cancers, Invitae will be able to help clinicians ...

Read more


Invitae expands existing credit facility to provide up to $40.0 million in available growth capital

Invitae expands existing credit facility to provide up to $40.0 million in available growth capital

February 27, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it has reached an agreement with Oxford Finance, LLC to expand its existing loan and security agreement by $20.0 million, bringing the total remaining capital available under the agreement to $40.0 million. This increase in net borrowing ability provides additional financial flexibility in 2018 as Invitae seeks to grow the size and scope of its genome network.

Invitae received gross proceeds of $40 ...

Read more


Invitae to present at the Cowen and Company 38th Annual Health Care Conference

Invitae to present at the Cowen and Company 38th Annual Health Care Conference

February 26, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will present at the Cowen and Company 38th Annual Health Care Conference in Boston on Monday, March 12, 2018 at 11:20 a.m. Eastern / 8:20 a.m. Pacific in Boston, Massachusetts.

A live webcast of the presentation may be accessed by visiting the investors section of the company’s website at ir.invitae.com. A replay of ...

Read more


Invitae reports over 150% volume and over 170% revenue growth for 2017

Invitae reports over 150% volume and over 170% revenue growth for 2017

February 12, 2018

Annual test volume exceeds high end of guidance

Robust test volume and revenue growth expected to continue in 2018 and beyond

Management hosting conference call and webcast today at 4:30pm Eastern/1:30pm Pacific

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced financial and operating results for the fourth quarter and full year ended December 31, 2017.

“Over the past year, we have made significant strategic investments that we believe uniquely position our ...

Read more


Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference

Invitae to participate in two upcoming investor conferences, including the 2018 BIO CEO & Investor Conference and Leerink Partners 7th Annual Global Healthcare Conference

January 31, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that Sean George, chief executive officer of Invitae, will participate in two upcoming investor conferences being held in New York City.

Sean George will present at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 10:00 a.m. Eastern / 7:00 a.m. Pacific. Additionally, Sean George will participate in a fireside chat at the Leerink Partners 7th Annual Global Healthcare ...

Read more


Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018

Invitae to announce fourth quarter and year-end 2017 financial results on February 12, 2018

January 29, 2018

Invitae Corporation (NYSE: NVTA), one of the fastest growing genetic information companies, today announced that it will report its fourth quarter and year-end 2017 financial results on Monday, February 12, 2018 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent developments.

The dial-in numbers for the conference call are (866) 393-4306 for domestic callers and (734) 385-2616 for international callers, and ...

Read more